Please login to the form below
SCLC
This page shows the latest SCLC news and features for those working in and with pharma, biotech and healthcare.
Roche's Tecentriq reduces risk of disease recurrence or death by 34% in some NSCLC patients
Tecentriq is currently approved for the front-line treatment of small cell lung cancer (SCLC), a market where the checkpoint inhibitor has been able to carve a niche away from the ... SCLC is less common than NSCLC but tends to be more aggressive,
Latest news
-
Roche’s Tecentriq yields positive data in early stage NSCLC
Keytruda has become a new standard-of-care for the treatment of newly-diagnosed NSCLC, although this immunotherapy failed to demonstrate the same benefit in SCLC. ... SCLC is less common than NSCLC but tends to be more aggressive, growing more quickly
-
FDA advisory committee to review oncology accelerated approvals
Similarly, BMS decided to withdraw the US indication for PD-1 inhibitor Opdivo (nivolumab) in SCLC which has progressed following prior therapies. ... As with Keytruda, Opdivo was granted an accelerated approval in this indication but subsequent
-
MSD withdraws Keytruda’s US indication for small cell lung cancer
The US Food and Drug Administration (FDA) granted Keytruda (pembrolizumab) an accelerated approval for the treatment of third line SCLC in June 2019. ... However, the SCLC market has been cornered by rival checkpoint inhibitors, including Roche’s
-
New dosing option for AZ’s Imfinzi approved in the EU and UK
The new dosing regimen is consistent with Imfinzi’s approved dosing in extensive-stage small cell lung cancer (ES-SCLC). ... of 10mg/kg approval in NSCLC and the CASPIAN phase 3 trial which used a four-week fixed-dose regimen in ES-SCLC.
-
Jazz Pharma’s SCLC drug fails to meet primary endpoint in combo trial
The drug scored conditional approved as a monotherapy in the metastatic, second-line setting for SCLC by the US Food and Drug Administration (FDA) n June. ... We look forward to the further development of lurbinectedin in SCLC and other tumours, both as
Roche’s Tecentriq yields positive data in early stage NSCLC
FDA advisory committee to review oncology accelerated approvals
MSD withdraws Keytruda’s US indication for small cell lung cancer
New dosing option for AZ’s Imfinzi approved in the EU and UK
Jazz Pharma’s SCLC drug fails to meet primary endpoint in combo trial
More from news
Approximately 6 fully matching, plus 37 partially matching documents found.
Latest Intelligence
-
Deal Watch February 2017
triple-negative breast cancer (TNBC), small-cell lung cancer (SCLC), non-small-cell lung cancer (NSCLC) and pancreatic cancer. .
-
Deal Watch April 2016
Rova-T showed a 44% overall response rate in DLL-expressing small cell lung cancer (SCLC) patients who had failed one or more standard therapies.
-
Deal Watch November 2015
July finalised a $730m exclusive deal with Boehringer Ingelheim for HM61713, an orally active third generation EGFR agent in small cell lung cancer (SCLC).
Deal Watch February 2017
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Medical Writers (All levels) Editorial / Scientific Leads & ...
-
Highly Competitive Remuneration packages
- Senior Account Management Trainer, Medical Communications, Londo...
-
Highly competitive salary
- Account Director, Medical & Brand Communications, London/ SE...
-
Highly competitive salary
- Freelance Scientific Director, Medical Communications, London/ S...
-
Highly competitive salary
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
- Senior Account Director, Medical & Brand Communications, Lon...
-
Highly competitive salary
-
CEO Pricing & Market Access, UK
-
Six figure salary
- Editorial Director - UK, , EUROPE, REMOTE.
-
Highly Competitive Salary, Bonus &Benefits
- First oral antiviral drug for COVID-19 reviewed by Health Canada
- Embattled Biogen talks up Aduhelm
- David Hunt launches independent agency The Considered
- EU “still interested” in Valneva COVID vaccine despite UK snub
- FDA’s director and deputy director of its Office of Vaccines Research & Review resign
- Merck’s anti-COVID drug molnupiravir moves to phase 3 for prevention
- Will most electronic consumer goods turn into medical devices after the MDR?
- AstraZeneca’s Imfinzi provides sustained survival benefit for lung cancer patients
- Biogen’s Vumerity recommended by CHMP in MS
- All change – how untangling human behaviour can encourage better health
- Solving healthcare problems
- New data from Moderna supports COVID boosters
No results were found
Latest intelligence
- All change – how untangling human behaviour can encourage better health
- Driving better patient outcomes through clear, achievable practical steps that are underpinned by transparent evidence...
- Health literacy in the time of COVID-19
- In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health...
- Rare thoughts & outcomes - navigating pathways to better outcomes in rare
- ...
